Treatment Options for Chronic Urticaria
ConditionChronic Urticaria
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age13-60
SponsorSheikh Zayed Medical College
About this trial
chronic urticaria is one of the most common dermatological disease affecting many people, exploring most treatment options for its treatment is need of an hour.
Our study aim to compare the efficacy of Autologous Serum Therapy (AST) with levocetirizine in Chronic Urticaria patients
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: 13-60 years
Gender: Both male and female
Patients having urticaria for more than 6 weeks diagnosed clinically
Disqualifiers
Pregnancy and lactating females
Patients who are immunosuppressed either due to medication or disease.
Patients suffering from chronic diseases i-e chronic liver disease, chronic kidney disease.
Patients taking steroids in last 2 weeks.
Trial design
Design model
Parallel
Treatments tested in this trial
Autologous serum therapy
Drug5 ml of blood will be collected and centrifuged at 3000 r.p.m for 10 min to obtain serum,2 ml of the serum will be injected into the gluteus muscle. We will give the patients 9 injections of Autologous Serum intramuscularly once a week
Oral levocetirizine
DrugGroup B will receive oral levocetirizine 5mg 1 tablet HS.
Treatment groups
72 Participants
are divided into 2 treatment groupsGroup A: Autologous serum therapy groupActive comparator 1 intervention
Group B: levocetirizine groupActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
COMPARISON OF OUTCOME OF AUTOLOGOUS SERUM THERAPY VS LEVOCETRIZINE IN THE TREATMENT OF CHRONIC URTICARIA
Efficacy will be assessed clinically at each follow up visit. Final efficacy of each treatment will be determined at last follow up visit( i.e. at 7th week after start of treatment).The final efficacy will be divided into following groups on the basis of clinical resolution of disease: 1. Excellent efficacy: It is defined as greater than 80% reduction in the frequency of urticaria episodes per week as measured from baseline 2. moderate efficacy: It is defined as 50% to less than 80% reduction in number of urticaria episodes per week as measured from baseline healing of urticaria from the baseline. 3.non-efficaceos: It is defined as less than a 50% reduction in the frequency of urticaria episodes per week from baseline.
Time frame
Clinical assessment for efficacy will be done monthly for 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: